Sophie Malekzadeh-Milani1, Magalie Ladouceur1, Mehul Patel1, Fazia-Marie Boughenou1, Laurence Iserin1, Damien Bonnet2, Younes Boudjemline3. 1. Centre de Référence Malformations Cardiaques Congénitales Complexes (M3C), Necker Hospital for Sick Children-HEGP, AP-HP, Paris, France. 2. Centre de Référence Malformations Cardiaques Congénitales Complexes (M3C), Necker Hospital for Sick Children-HEGP, AP-HP, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France. 3. Centre de Référence Malformations Cardiaques Congénitales Complexes (M3C), Necker Hospital for Sick Children-HEGP, AP-HP, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France. Electronic address: younes.boudjemline@nck.aphp.fr.
Abstract
BACKGROUND: Percutaneous pulmonary valve replacement (PPVR) has achieved standard of care for the management of dysfunctional right ventricular outflow tract. AIM: Because of increasing reports of Melody(®) valve (Medtronic, Inc., Minneapolis, MN, USA) infective endocarditis (IE), we aimed to evaluate its incidence and predictors of occurrence. METHODS: We collected data on all patients who received a Melody valve in the pulmonary position from 2009 to 2012. RESULTS: A total of 86 consecutive patients underwent PPVR from 2009 to 2012; of these, five developed IE (5.8%). Freedom from IE was 91% at 50 months. Baseline demographics, type of conduit, PPVR procedural success, residual gradients and in situ duration of Melody valve were similar in IE and non-IE patients. A significant number of IE patients had additional unprotected invasive procedures during follow-up and abruptly discontinued antiplatelet therapy (P=0.0139 and P=0.002, respectively). The cumulative probability of survival without cardiovascular events for IE patients was 20% at 20 months, compared with 98.1% for non-IE patients (P<0.0001). Death was statistically associated with IE. CONCLUSION: Early- and late-onset IE of the Melody valve is emerging as a catastrophic complication of PPVR. Abrupt aspirin discontinuation and additional unprotected invasive procedures during follow-up are significant predictors of Melody valve IE. Owing to its rapidly progressive nature, aggressive invasive management should not be delayed.
BACKGROUND: Percutaneous pulmonary valve replacement (PPVR) has achieved standard of care for the management of dysfunctional right ventricular outflow tract. AIM: Because of increasing reports of Melody(®) valve (Medtronic, Inc., Minneapolis, MN, USA) infective endocarditis (IE), we aimed to evaluate its incidence and predictors of occurrence. METHODS: We collected data on all patients who received a Melody valve in the pulmonary position from 2009 to 2012. RESULTS: A total of 86 consecutive patients underwent PPVR from 2009 to 2012; of these, five developed IE (5.8%). Freedom from IE was 91% at 50 months. Baseline demographics, type of conduit, PPVR procedural success, residual gradients and in situ duration of Melody valve were similar in IE and non-IE patients. A significant number of IE patients had additional unprotected invasive procedures during follow-up and abruptly discontinued antiplatelet therapy (P=0.0139 and P=0.002, respectively). The cumulative probability of survival without cardiovascular events for IE patients was 20% at 20 months, compared with 98.1% for non-IE patients (P<0.0001). Death was statistically associated with IE. CONCLUSION: Early- and late-onset IE of the Melody valve is emerging as a catastrophic complication of PPVR. Abrupt aspirin discontinuation and additional unprotected invasive procedures during follow-up are significant predictors of Melody valve IE. Owing to its rapidly progressive nature, aggressive invasive management should not be delayed.
Authors: Bart W Driesen; Evangeline G Warmerdam; Gert-Jan Sieswerda; Folkert J Meijboom; Mirella M C Molenschot; Pieter A Doevendans; Gregor J Krings; Arie P J van Dijk; Michiel Voskuil Journal: Curr Cardiol Rev Date: 2019
Authors: Arpine Davtyan; Peter W Guyon; Hannah R El-Sabrout; Reid Ponder; Nanda Ramchandar; Rachel Weber; Wagih Zayed; Kanishka Ratnayaka; John J Nigro; John W Moore; Holly Bauser-Heaton; Laith Alshawabkeh; Ryan R Reeves; Daniel Levi; Jamil Aboulhosn; Henri Justino; John Bradley; Howaida G El-Said Journal: Pediatr Cardiol Date: 2021-12-11 Impact factor: 1.655
Authors: Clara Stammnitz; Dörte Huscher; Ulrike M M Bauer; Aleksandra Urban; Johannes Nordmeyer; Stephan Schubert; Joachim Photiadis; Felix Berger; Sabine Klaassen Journal: J Am Heart Assoc Date: 2022-02-18 Impact factor: 5.501
Authors: Arka Chatterjee; Navkaranbir S Bajaj; William S McMahon; Marc G Cribbs; Jeremy S White; Amrita Mukherjee; Mark A Law Journal: J Am Heart Assoc Date: 2017-08-04 Impact factor: 5.501
Authors: Bjorn Cools; Werner Budts; Ruth Heying; Derize Boshoff; Benedicte Eyskens; Stefan Frerich; Els Troost; Marc Gewillig Journal: Int J Cardiol Heart Vasc Date: 2015-03-06
Authors: Mohammad Abdelghani; Martina Nassif; Nico A Blom; Martijn S Van Mourik; Bart Straver; David R Koolbergen; Jolanda Kluin; Jan G Tijssen; Barbara J M Mulder; Berto J Bouma; Robbert J de Winter Journal: J Am Heart Assoc Date: 2018-06-22 Impact factor: 5.501